Drug Research

Sygnature Discovery and UBE Corporation have begun a collaboration on a Hit-to-Lead program to identify SHP2 degraders.  SHP2 is a tyrosine-specific phosphatase implicated in human cancers and the objective is to develop potent bifunctional compounds with excellent ADME and PK...

It's important to highlight that aseptic fill finish operations demand skilled personnel, specialized automated equipment, a controlled cleanroom environment, and constant supervision to maintain the sterility and safety of the final pharmaceutical product. Nevertheless, due to the high costs associated...

While the pharmaceutical industry has traditionally been seen as recession-proof, with a constant demand for medicines and new treatment options, it currently faces significant challenges. Economic uncertainty is on the rise, increasing the risks associated with early drug discovery,...

Sever Pharma Solutions, a leading pharmaceutical contract development and manufacturing organization (CDMO), has announced the groundbreaking of its new high potency active pharmaceutical ingredients (HPAPI) manufacturing suites. The company’s investment in these new state-of-the-art manufacturing facilities will allow them...

Bora Health, a global design, development and distribution partner of pharmaceuticals and health foods and part of the Bora group, has announced its merged with Sunway Biotech, a leading ingredients manufacturer, and research and development (R&D) organization. Resulting in...

Based on current market analyses, global pharmaceutical spending is projected to reach approximately $1,742 billion by 2025. Concurrently, spending on COVID-19 vaccines and therapeutics is anticipated to reach around $53 billion worldwide in the same year. Two predominant trends currently...

Samsung Biologics announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance. Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug...